News
Dermacyte Matrix - Merakris Therapeutics
04/07/2025
Merakris Therapeutics announced positive results from a Phase 2 study evaluating Dermacyte Liquid (MTX-001), a subcutaneous amniotic fluid product for refractory VLUs. Of the nine patients, 66.7% of patients achieved complete closure at one month follow-up.


